NDAINTRAVENOUSSOLUTION
Approved
Dec 2012
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
4
Data completeness
5/8 — Partial
PHENYLEPHRINE HYDROCHLORIDE (phenylephrine hydrochloride) by Hikma is α-1 adrenergic receptor agonist. Approved for nasal congestion, seasonal allergic rhinitis, vasomotor rhinitis and 3 more indications. First approved in 2012.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Phenylephrine hydrochloride is an α-1 adrenergic receptor agonist administered intravenously as a solution for nasal congestion and upper respiratory symptoms. It treats seasonal allergic rhinitis, vasomotor rhinitis, rhinorrhea, and sneezing by stimulating alpha-1 adrenergic receptors. The IV formulation is primarily used in acute clinical settings for hemodynamic support and nasal decongestion.
Peak10.4 years to LOE
Product is at peak commercial maturity with no competitive pricing pressure; likely stable, smaller brand team focused on maintenance and hospital account management.
Mechanism of Action
α-1 adrenergic receptor agonist.
Indications (6)
Worked on PHENYLEPHRINE HYDROCHLORIDE at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.